Company Overview and News

4
Cryptocurrencies jump as ripple optimism lifts battered market

2018-09-21 theedgemarkets
(Sept 21): Cryptocurrencies surged on Friday as optimism surrounding Ripple Labs Inc’s plans for using a digital coin spread, lifting peers that have lost more than US$600 billion of value since January.
BNC PNC PNUCL PNCFO SANT SAN

4
JPMorgan (JPM) Cheers Shareholders With 43% Dividend Hike

2018-09-19 zacks
JPMorgan’s (JPM - Free Report) board of directors has announced a 42.9% hike in its quarterly dividend. The revised dividend of 80 cents per share will be paid on Oct 31 to shareholders of record as of Oct 5. Based on the last day’s closing price of $114.30 per share, the dividend yield is 2.8%. The hike comes as part of the company’s 2018 capital plan which was approved by the Federal Reserve this June.
STI UNP PNC STI-A PNUCL PNCFO

4
Blockchain startup Ripple signs up PNC as a customer for its payment tech

2018-09-19 reuters
NEW YORK (Reuters) - A division of PNC Financial Services Group Inc (PNC.N) will use technology built by startup Ripple to process international payments, the companies said on Wednesday, a possible precursor to the use of blockchain in mainstream finance.
PNC PNUCL PNCFO

4
Blockchain startup Ripple signs up PNC as a customer for its payment tech

2018-09-19 channelnewsasia
NEW YORK: A division of PNC Financial Services Group Inc will use technology built by startup Ripple to process international payments, the companies said on Wednesday, a possible precursor to the use of blockchain in mainstream finance.
PNC PNUCL PNCFO

4
The PNC Financial Services (PNC) Presents At Barclays Global Financial Services Conference 2018 - Slideshow

2018-09-12 seekingalpha
The following slide deck was published by PNC Financial Services Group, Inc. in conjunction with this event.
PNC PNUCL PNCFO

27
The Zacks Analyst Blog Highlights: Visa, PNC, SAP, Sanofi and Ross

2018-08-30 zacks
Chicago, IL –August 30, 2018 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Visa (V - Free Report) , PNC Financial Services Group (PNC - Free Report) , SAP SE (SAP - Free Report) , Sanofi (SNY - Free Report) and Ross Stores (ROST - Free Report) .
CY SAPGF PNCFO NVMI ROST SNY SAP V PNC PNUCL URBN SMG

17
Top Research Reports for Visa, PNC Financial & SAP

2018-08-29 zacks
The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Visa (V), PNC Financial Services Group (PNC) and SAP SE (SAP). These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.
REGN SAPGF PNCFO ROST SNY EOG SAP V EQT PNC VEEV PNUCL NVS CSX OGE

9
Lagging Oil Industry Weighs On Mexico’s Economy

2018-08-25 oilprice
Haley Zaremba is a writer and journalist based in Mexico City. She has extensive experience writing and editing environmental features, travel pieces, local news in the…
C PNCFO CGBBW PNC PNUCL

61
TITXD / Titan Medical Inc - Stock Institutional Ownership and Shareholders - Fintel.io

2018-08-20 fintel.io - 2
This group is for elite investors and traders that are dedicated to participating in an active community that wants to learn from each other, share their research, and work together to do deep analysis of securities. The moderator of this group taught securities analysis at UCLA and is dedicated to helping other investors improve their abilities.
WFCNP BTE TITXF TIXXF RBCDF ACHN TMDI BAC BMO MS TITXD WFC BMQZF BAC TMD RY PNCFO BMO RY PNC PNUCL BTE

12
SunTrust (STI) Rewards Shareholders With 25% Dividend Hike

2018-08-16 zacks - 1
SunTrust Banks, Inc.’s (STI - Free Report) board of directors has approved a 25% hike in the quarterly common stock dividend. The revised quarterly dividend is now 50 cents per share, up from the prior payout of 40 cents. This dividend is payable on Sep 17, to shareholders on record as of Aug 31, 2018. The hike comes as part of the company’s 2018 capital plan which was approved by the Federal Reserve in June.
HD NTRSP PNCFO KEY STI NTRS PNC STI-A PNUCL OXY

9
U.S. banks teach financial literacy with hands-on experience

2018-08-16 reuters
NEW YORK, Aug 16 (Reuters) - Last year, Abbey Jones’ high school routine had a twist.
PNC PNUCL PNCFO FITB FITBI

100
ETB / Eaton Vance Tax-Managed Buy-Write Income Fund - Stock Institutional Ownership and Shareholders - Fintel.io

2018-08-10 fintel.io
This group is for elite investors and traders that are dedicated to participating in an active community that wants to learn from each other, share their research, and work together to do deep analysis of securities. The moderator of this group taught securities analysis at UCLA and is dedicated to helping other investors improve their abilities.
WFCNP ETB NYMX EV AMP TWMJF UBS WEED MS WFC PNCFO CGC PNC PNUCL ULSGF IVZ

34
CEF Opportunity: 5.5% Yield, 20% Upside, Well-Positioned For Rising Rates, Diversified Holdings

2018-08-09 seekingalpha
I love Mario Gabelli. I have been following him from the first time I saw him speak on CNBC. He has a knack for picking great stocks.
CVS HON 8685 STT AVF PNCFO GDV WM AIG PFIZER PNC SWMAF VZ BA PFE WFCNP SWMAY VZA BOE XYL WFC HON PFZ DWDP PEP PNUCL 500680

4
NYC Area’s Tax-Reform Refugees Fuel Luxury-Home Boom in Florida - Bloomberg

2018-08-08 bloomberg
Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.
RDFN PNC PNUCL PNCFO

23
JPMorgan’s Jamie Dimon was best paid CEO last year—but look who came fourth - MarketWatch

2018-07-20 marketwatch - 1
Scandal-ridden Wells Fargo’s CEO beat out six regional banks to be fourth best-paid bank CEO in 2017
GLSSP JBK TFG PNCFO CGBBW PNC WFCNP GS WFC C GSC GSJ FHN PNUCL GJS

Related Articles

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...

EKSO: Ekso Bionics Holdings Analysis and Research Report

2018-09-18 - Asif

Overview The company design, develop and sell exoskeleton technology to augment human strength, endurance and mobility. The company's exoskeleton technology serves multiple markets and can be used both by able-bodied users as well as by persons with physical disabilities. Ekso Bionics has sold, rented or leased devices that (a) enable individuals with neurological conditions affecting gait (stroke and spinal cord injury) to rehabilitate and to walk again and (b) allow industrial workers to perform heavy duty work for extended periods. Today, its medical exoskeleton, Ekso GT, is used as a rehabilitation tool to allow physicians and therapists to rehabilitate patients who have suffered a stroke or spinal cord injury. With its unique features designed specifically for hospitals and its proprietary SmartAssist software, Ekso GT allows for the early mobilization of patients, with high step count and high dosage treatments. The intent is to allow the patient’s central nervous syst...

AGRX: Agile Therapeutics Analysis and Research Report

2018-09-18 - Asif

Overview Agile Therapeutics is a forward-thinking women’s healthcare company dedicated to fulfilling the unmet health needs of today’s women. Twirla® and its other current potential product candidates are designed to provide women with contraceptive options that offer greater convenience and facilitate compliance. The company's lead product candidate, Twirla, also known as AG200-15, is a once-weekly prescription contraceptive patch that is at the end of Phase 3 clinical development. Since its inception in 1997, Agile Therapeutics has devoted substantial resources to developing Twirla, building its intellectual property portfolio, business planning, raising capital and providing general and administrative support for these operations. The company incurred research and development expenses of $14.4 million, $20.9 million and $25.6 million during the years ended December 31, 2017, 2016 and 2015, respectively. The company incurred research and development expenses of $2.4 milli...